Once-weekly risedronate in men with osteoporosis: Results of a 2-Year, placebo-controlled, double-blind, multicenter study

Steven Boonen, Eric Orwoll, Dietrich Wenderoth, Karen J. Stoner, Rachelle Eusebio, Pierre D. Delmas

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

Male osteoporosis is increasingly recognized as a major public health issue. This multinational, 2-yr, randomized, double-blind, placebo-controlled study was conducted to determine the efficacy and safety of 35 mg once-a-week risedronate in men with osteoporosis. Patients had to be men ≥30 yr old, with lumbar spine T-score ≤ -2.5 and femoral neck T-score ≤ -1 SD or lumbar spine T-score ≤ -1 and femoral neck T-score ≤ -2 SD (based on young normal men). Patients were randomized 2:1 to risedronate 35 mg once a week or placebo for 2 yr; all patients took 1000 mg elemental calcium and 400-500 IU vitamin D daily. Lumbar spine BMD at month 24 using last observation carried forward was the primary endpoint. Other endpoints included lumbar spine BMD at time points other than month 24, proximal femur BMD, bone turnover markers (BTMs), new vertebral fractures, clinical fractures, and adverse event (AE) assessment. There were 284 men enrolled in the study. Treatment with risedronate resulted in a significant increase from baseline to endpoint in lumbar spine BMD compared with placebo (4.5%; 95% CI: 3.5%, 5.6%; ρ <0.001). Few new vertebral and nonvertebral fractures were reported, with no differences in fracture rates between the two groups. There was a significant (ρ <0.01) reduction from baseline in BTMs for the risedronate group compared with placebo at all time points. No apparent differences in the pattern or distribution of AEs including serious and upper gastrointestinal AEs were observed. Risedronate therapy was well tolerated during this 2-yr study and was rapidly effective as indicated by significant BTM decreases at month 3 and BMD increases at month 6 (the earliest time points tested). The effects of risedronate treatment on BMD and BTMs in this study were similar to those previously shown to be associated with fracture risk reductions in women with postmenopausal osteoporosis.

Original languageEnglish (US)
Pages (from-to)719-725
Number of pages7
JournalJournal of Bone and Mineral Research
Volume24
Issue number4
DOIs
StatePublished - Apr 2009

Fingerprint

Double-Blind Method
Osteoporosis
Multicenter Studies
Bone Remodeling
Placebos
Spine
Femur Neck
Fracture Fixation
Postmenopausal Osteoporosis
Risk Reduction Behavior
Vitamin D
Femur
Risedronate Sodium
Therapeutics
Public Health
Observation
Calcium
Safety

Keywords

  • Bisphosphonate
  • BMD
  • Bone turnover
  • Male osteoporosis
  • Risedronate

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Once-weekly risedronate in men with osteoporosis : Results of a 2-Year, placebo-controlled, double-blind, multicenter study. / Boonen, Steven; Orwoll, Eric; Wenderoth, Dietrich; Stoner, Karen J.; Eusebio, Rachelle; Delmas, Pierre D.

In: Journal of Bone and Mineral Research, Vol. 24, No. 4, 04.2009, p. 719-725.

Research output: Contribution to journalArticle

Boonen, Steven ; Orwoll, Eric ; Wenderoth, Dietrich ; Stoner, Karen J. ; Eusebio, Rachelle ; Delmas, Pierre D. / Once-weekly risedronate in men with osteoporosis : Results of a 2-Year, placebo-controlled, double-blind, multicenter study. In: Journal of Bone and Mineral Research. 2009 ; Vol. 24, No. 4. pp. 719-725.
@article{ba2d2c364d29427fad91adced590f3b2,
title = "Once-weekly risedronate in men with osteoporosis: Results of a 2-Year, placebo-controlled, double-blind, multicenter study",
abstract = "Male osteoporosis is increasingly recognized as a major public health issue. This multinational, 2-yr, randomized, double-blind, placebo-controlled study was conducted to determine the efficacy and safety of 35 mg once-a-week risedronate in men with osteoporosis. Patients had to be men ≥30 yr old, with lumbar spine T-score ≤ -2.5 and femoral neck T-score ≤ -1 SD or lumbar spine T-score ≤ -1 and femoral neck T-score ≤ -2 SD (based on young normal men). Patients were randomized 2:1 to risedronate 35 mg once a week or placebo for 2 yr; all patients took 1000 mg elemental calcium and 400-500 IU vitamin D daily. Lumbar spine BMD at month 24 using last observation carried forward was the primary endpoint. Other endpoints included lumbar spine BMD at time points other than month 24, proximal femur BMD, bone turnover markers (BTMs), new vertebral fractures, clinical fractures, and adverse event (AE) assessment. There were 284 men enrolled in the study. Treatment with risedronate resulted in a significant increase from baseline to endpoint in lumbar spine BMD compared with placebo (4.5{\%}; 95{\%} CI: 3.5{\%}, 5.6{\%}; ρ <0.001). Few new vertebral and nonvertebral fractures were reported, with no differences in fracture rates between the two groups. There was a significant (ρ <0.01) reduction from baseline in BTMs for the risedronate group compared with placebo at all time points. No apparent differences in the pattern or distribution of AEs including serious and upper gastrointestinal AEs were observed. Risedronate therapy was well tolerated during this 2-yr study and was rapidly effective as indicated by significant BTM decreases at month 3 and BMD increases at month 6 (the earliest time points tested). The effects of risedronate treatment on BMD and BTMs in this study were similar to those previously shown to be associated with fracture risk reductions in women with postmenopausal osteoporosis.",
keywords = "Bisphosphonate, BMD, Bone turnover, Male osteoporosis, Risedronate",
author = "Steven Boonen and Eric Orwoll and Dietrich Wenderoth and Stoner, {Karen J.} and Rachelle Eusebio and Delmas, {Pierre D.}",
year = "2009",
month = "4",
doi = "10.1359/jbmr.081214",
language = "English (US)",
volume = "24",
pages = "719--725",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Once-weekly risedronate in men with osteoporosis

T2 - Results of a 2-Year, placebo-controlled, double-blind, multicenter study

AU - Boonen, Steven

AU - Orwoll, Eric

AU - Wenderoth, Dietrich

AU - Stoner, Karen J.

AU - Eusebio, Rachelle

AU - Delmas, Pierre D.

PY - 2009/4

Y1 - 2009/4

N2 - Male osteoporosis is increasingly recognized as a major public health issue. This multinational, 2-yr, randomized, double-blind, placebo-controlled study was conducted to determine the efficacy and safety of 35 mg once-a-week risedronate in men with osteoporosis. Patients had to be men ≥30 yr old, with lumbar spine T-score ≤ -2.5 and femoral neck T-score ≤ -1 SD or lumbar spine T-score ≤ -1 and femoral neck T-score ≤ -2 SD (based on young normal men). Patients were randomized 2:1 to risedronate 35 mg once a week or placebo for 2 yr; all patients took 1000 mg elemental calcium and 400-500 IU vitamin D daily. Lumbar spine BMD at month 24 using last observation carried forward was the primary endpoint. Other endpoints included lumbar spine BMD at time points other than month 24, proximal femur BMD, bone turnover markers (BTMs), new vertebral fractures, clinical fractures, and adverse event (AE) assessment. There were 284 men enrolled in the study. Treatment with risedronate resulted in a significant increase from baseline to endpoint in lumbar spine BMD compared with placebo (4.5%; 95% CI: 3.5%, 5.6%; ρ <0.001). Few new vertebral and nonvertebral fractures were reported, with no differences in fracture rates between the two groups. There was a significant (ρ <0.01) reduction from baseline in BTMs for the risedronate group compared with placebo at all time points. No apparent differences in the pattern or distribution of AEs including serious and upper gastrointestinal AEs were observed. Risedronate therapy was well tolerated during this 2-yr study and was rapidly effective as indicated by significant BTM decreases at month 3 and BMD increases at month 6 (the earliest time points tested). The effects of risedronate treatment on BMD and BTMs in this study were similar to those previously shown to be associated with fracture risk reductions in women with postmenopausal osteoporosis.

AB - Male osteoporosis is increasingly recognized as a major public health issue. This multinational, 2-yr, randomized, double-blind, placebo-controlled study was conducted to determine the efficacy and safety of 35 mg once-a-week risedronate in men with osteoporosis. Patients had to be men ≥30 yr old, with lumbar spine T-score ≤ -2.5 and femoral neck T-score ≤ -1 SD or lumbar spine T-score ≤ -1 and femoral neck T-score ≤ -2 SD (based on young normal men). Patients were randomized 2:1 to risedronate 35 mg once a week or placebo for 2 yr; all patients took 1000 mg elemental calcium and 400-500 IU vitamin D daily. Lumbar spine BMD at month 24 using last observation carried forward was the primary endpoint. Other endpoints included lumbar spine BMD at time points other than month 24, proximal femur BMD, bone turnover markers (BTMs), new vertebral fractures, clinical fractures, and adverse event (AE) assessment. There were 284 men enrolled in the study. Treatment with risedronate resulted in a significant increase from baseline to endpoint in lumbar spine BMD compared with placebo (4.5%; 95% CI: 3.5%, 5.6%; ρ <0.001). Few new vertebral and nonvertebral fractures were reported, with no differences in fracture rates between the two groups. There was a significant (ρ <0.01) reduction from baseline in BTMs for the risedronate group compared with placebo at all time points. No apparent differences in the pattern or distribution of AEs including serious and upper gastrointestinal AEs were observed. Risedronate therapy was well tolerated during this 2-yr study and was rapidly effective as indicated by significant BTM decreases at month 3 and BMD increases at month 6 (the earliest time points tested). The effects of risedronate treatment on BMD and BTMs in this study were similar to those previously shown to be associated with fracture risk reductions in women with postmenopausal osteoporosis.

KW - Bisphosphonate

KW - BMD

KW - Bone turnover

KW - Male osteoporosis

KW - Risedronate

UR - http://www.scopus.com/inward/record.url?scp=65549099590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549099590&partnerID=8YFLogxK

U2 - 10.1359/jbmr.081214

DO - 10.1359/jbmr.081214

M3 - Article

C2 - 19049326

AN - SCOPUS:65549099590

VL - 24

SP - 719

EP - 725

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 4

ER -